Table 3.
Prognostic value of KRAS status analyzed in tumor tissue and plasma by different laboratory assays in colorectal cancer patients
| Prognostic value | ||||||||
|---|---|---|---|---|---|---|---|---|
| Tissue and testing method | PFS | OS | ||||||
| KRAS status | Median PFS (mo) | 95% Cl | P value * | Median OS (mo) | 95% Cl | P value * | ||
| Tumor | ||||||||
| Sequencing | Wild-type | 260 | 6·1 | 4·5-7·7 | ·473 | 18·3 | 16·2-20·4 | ·064 |
| Mutated | 156 | 5·8 | 3·4-8·2 | 15·9 | 14·4-17·4 | |||
| PNA-PCR | Wild-type | 221 | 6·2 | 4·5-7·9 | ·360 | 19·5 | 17·2-21·8 | ·025 |
| Mutated | 195 | 5·9 | 4·0-7·8 | 16·9 | 15·6-18·2 | |||
| Plasma | ||||||||
| Sequencing | Wild-type | 201 | 6·1 | 5·5-6·6 | ·489 | 18·3 | 15·9-20·7 | ·037 |
| Mutated | 41 | 5·4 | 4·9-5·8 | 15·7 | 9·3-22·1 | |||
| PNA-PCR | Wild-type | 166 | 6·1 | 5·5-6·7 | ·274 | 19·1 | 16·8-21·4 | ·009 |
| Mutated | 76 | 5·7 | 5·3-6·1 | 15·7 | 13·0-18·4 | |||
*Log-rank test. All statistical tests were two-sided.
CI, confidence interval; mo, month; OS, overall survival; PFS, progression-free survival; PNA-PCR, peptide-nucleic-acid-mediated polymerase chain reaction clamping.